Research programme: CFTR channel modulators - Cystic Fibrosis Foundation Therapeutics/EPIX

Drug Profile

Research programme: CFTR channel modulators - Cystic Fibrosis Foundation Therapeutics/EPIX

Alternative Names: CFTR regulators - Cystic Fibrosis Foundation Therapeutics/EPIX

Latest Information Update: 16 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; EPIX Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 01 Oct 2009 Discontinued - Preclinical for Cystic fibrosis in USA (unspecified route)
  • 08 Apr 2008 CFFT increases potential payments to EPIX under new agreement
  • 24 Jan 2008 EPIX receives milestone payment from Cystic Fibrosis Foundation Therapeutics for development of CFTR ion channel model
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top